Search

Your search keyword '"Zhang, Bo‐Dou"' showing total 22 results
Start Over Author "Zhang, Bo‐Dou"
22 results on '"Zhang, Bo‐Dou"'

8. CASTING: A Potent Supramolecular Strategy to Cytosolically Deliver STING Agonist for Cancer Immunotherapy and SARS-CoV-2 Vaccination

Author

Wu, Jun-Jun, primary, Chen, Fang-Yuan, additional, Han, Bei-Bei, additional, Zhang, Hong-Qing, additional, Zhao, Lang, additional, Zhang, Zhe-Rui, additional, Li, Juan-Juan, additional, Zhang, Bo-Dou, additional, Zhang, Ya-Nan, additional, Yue, Yu-Xin, additional, Hu, Hong-Guo, additional, Li, Wen-Hao, additional, Zhang, Bo, additional, Chen, Yong-Xiang, additional, Guo, Dong-Sheng, additional, and Li, Yan-Mei, additional

Published
2023
Full Text
View/download PDF

20. Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice

Author

Chen, Pu-Guang, Hu, Hong-Guo, Sun, Zhan-Yi, Li, Qian-Qian, Zhang, Bo-Dou, Wu, Jun-Jun, Li, Wen-Hao, Zhao, Yu-Fen, Chen, Yong-Xiang, and Li, Yan-Mei

Abstract

Constructing an effective therapeutic cancer vaccine is very attractive and promising for cancer immunotherapy. However, the poor immunogenicity of tumor antigens and suppression of the immune system in the tumor microenvironment are two major obstacles for developing effective cancer vaccines. Invariant NKT cells (iNKT cells), which are essential bridges between the innate and adaptive immune systems, can be rapidly activated by their agonists and, consequently, evoke whole immune systems. Herein, we conjugated a potent agonist of the iNKT cell, α-galactosylceramide (α-GalCer), with the tumor-associated MUC1 glycopeptide antigens as novel self-adjuvanting cancer vaccines through click chemistry. Immunological studies revealed that the mouse immune system was potently evoked and that high levels of tumor-specific IgG antibodies were elicited by vaccine conjugates without an external adjuvant. The produced antibodies could specifically recognize and bind to antigen-expressing cancer cells and, subsequently, induce cytotoxicity through complement-dependent cytotoxicity. Thus, the insertion of α-GalCer significantly improved the immunogenicity of the MUC1 glycopeptide and induced strong antigen-specific antitumor responses, indicating that α-GalCer is an effective built-in adjuvant for constructing potent chemical synthetic antitumor vaccines.

Published
2020
Full Text
View/download PDF

21. Pam3CSK4-CDGSFAugments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING

Author

Hu, Hong-Guo, Wu, Jun-Jun, Zhang, Bo-Dou, Li, Wen-Hao, and Li, Yan-Mei

Abstract

Cyclic dinucleotides (CDNs), agonists of stimulator of interferon genes (STING), are promising agents for immunotherapy. However, the application of CDNs has been limited by their instability and low transmembrane efficiency. Here, we introduced a conjugated adjuvant of STING and TLR1/2, Pam3CSK4-CDGSF. Conjugating CDGSFwith Pam3CSK4increased the stability and intracellular delivery. In addition, by synergistically activating the STING and TLR pathways, Pam3CSK4-CDGSFwas able to enhance immune activation. Both humoral and cellular immune responses were triggered by Pam3CSK4-CDGSFplus OVA (V4), and tumor growth was significantly inhibited after V4 administration. More importantly, V4 can also boost the antigen-specific CD8+ T cell response for cancer cell killing. Thus, the conjugated STING and TLR1/2 agonist Pam3CSK4-CDGSFcan serve as a potent adjuvant for vaccine construction to augment antitumor immunotherapy.

Published
2020
Full Text
View/download PDF

22. Pam 3 CSK 4 -CDG SF Augments Antitumor Immunotherapy by Synergistically Activating TLR1/2 and STING.

Author

Hu HG, Wu JJ, Zhang BD, Li WH, and Li YM

Subjects
Animals, Antibody Formation, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Humans, Immunity, Cellular, Mice, Neoplasms immunology, Toll-Like Receptor 1 agonists, Immunotherapy, Lipopeptides pharmacology, Membrane Proteins agonists, Neoplasms therapy, Toll-Like Receptor 2 agonists
Abstract

Cyclic dinucleotides (CDNs), agonists of stimulator of interferon genes (STING), are promising agents for immunotherapy. However, the application of CDNs has been limited by their instability and low transmembrane efficiency. Here, we introduced a conjugated adjuvant of STING and TLR1/2, Pam 3 CSK 4 -CDG SF . Conjugating CDG SF with Pam 3 CSK 4 increased the stability and intracellular delivery. In addition, by synergistically activating the STING and TLR pathways, Pam 3 CSK 4 -CDG SF was able to enhance immune activation. Both humoral and cellular immune responses were triggered by Pam 3 CSK 4 -CDG SF plus OVA (V4), and tumor growth was significantly inhibited after V4 administration. More importantly, V4 can also boost the antigen-specific CD8+ T cell response for cancer cell killing. Thus, the conjugated STING and TLR1/2 agonist Pam 3 CSK 4 -CDG SF can serve as a potent adjuvant for vaccine construction to augment antitumor immunotherapy.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results